SIMILAR EFFICACY FOLLOWING FOUR WEEKS TREATMENT OF ASTHMATICS WITH FORMOTEROL 12 μG B.D. DELIVERED BY TWO DIFFERENT DRY POWDER INHALERS: DIFFERENCES IN INHALER HANDLING

SUMMARY This randomised, multicentre, parallel‐group study compared the clinical efficacy and ease of handling of two dry powder inhalers delivering the long‐acting β 2 ‐agonist formoterol. After run‐in, 200 asthmatics on treatment with inhaled corticosteroids and still presenting with suboptimal asthma control were randomised to receive 12 μg formoterol twice daily via either the Aerolizer inhaler (Foradil ® Aerolizer™) or the Turbuhaler inhaler (Oxis® Turbuhaler®) for four weeks. Study variables included the mean morning pre‐medication peak expiratory flow (PEF) during the last seven days of treatment and the correct inhaler handling according to inhaler‐specific checklists. The mean difference in the effect on morning pre‐medication PEF was 13.86 l/min in favour of formoterol via the Aerolizer inhaler (90% confidence interval 2.50, 25.21) in the intent‐to‐treat population. Eighty‐six per cent of the patients under treatment with formoterol via the Turbuhaler inhaler performed correctly all the essential inhalation manoeuvres, whereas 98% of those on the Aerolizer inhaler did so. These results strongly suggest similar clinical efficacy with twice daily treatment of formoterol 12 μg metered dose delivered either by the Aerolizer, or the Turbuhaler device. They also suggest that handling the Aerolizer is easier than that of the Turbuhaler.